UCB SA (OTCMKTS:UCBJF – Get Free Report) gapped down prior to trading on Tuesday. The stock had previously closed at $305.59, but opened at $292.20. UCB shares last traded at $292.20, with a volume of 51 shares.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the company. Stephens restated an “overweight” rating on shares of UCB in a research report on Wednesday, October 21st. Jefferies Financial Group upgraded UCB to a “hold” rating in a report on Monday, August 3rd. Finally, Piper Sandler restated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, UCB currently has an average rating of “Moderate Buy”.
Read Our Latest Research Report on UCB
UCB Price Performance
The company has a fifty day moving average of $249.94 and a two-hundred day moving average of $285.63. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
About UCB
UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.
The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).
Featured Articles
- Five stocks we like better than UCB
- Off-Price, High-Yield: Why Ross Stores Is Defying the Retail Slump
- Whirlpool’s Stock Collapse Raises a Bigger Question About Its Recovery Potential
- Analysts Turn Bullish on Meta Platforms Despite Post-Earnings Fall
- Approaching Earnings Season, Are Pure Play Quantum Stocks Still a Good Bet?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
